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Adipose tissue-derived stem cells (ASCs) are a promising tool for the treatment of bone diseases or skeletal lesions, thanks to their
ability to potentially repair damaged tissue. One of the major limitations of ASCs is represented by the necessity to be isolated and
expanded through in vitro culture; thus, a strong interest was generated by the adipose stromal vascular fraction (SVF), the
noncultured fraction of ASCs. SVF is a heterogeneous cell population, directly obtained after collagenase treatment of adipose
tissue. In order to investigate and compare the bone-regenerative potential of SVF and ASCs, they were plated on SmartBone®,
a xenohybrid bone scaﬀold, already used in clinical practice with successful results. We showed that SVF plated on SmartBone,
in the presence of osteogenic factors, had better osteoinductive capabilities than ASCs, in terms of diﬀerentiation into bone cells,
mineralization, and secretion of soluble factors stimulating osteoblasts. Indeed, we observed an increasing area of new tissue
over time, with and without OM. These data strongly support an innovative idea for the use of adipose SVF and bone scaﬀolds
to promote tissue regeneration and repair, also thanks to an easier cell management preparation that allows a potentially larger
use in clinical applications.
1. Introduction
Regenerative medicine based on stem cell ability to poten-
tially repair injured tissues is a promising treatment for many
orthopaedic problems [1, 2]. Indeed, the availability of adult
stem cells, such as mesenchymal stem cells (MSCs), which
can be easily retrieved by adipose tissue, has dramatically
enlarged their potential ﬁeld of application [3–7]. One of
the major limitations of MSCs is represented by the necessity
to expand them through in vitro culturing, transforming
them into a pharmaceutical product with its restrictive
regulatory clearance and connected diﬃculties for clinical
routinary use. Thus, a strong interest was generated by the
stromal vascular fraction (SVF), the noncultured fraction of
MSCs, directly obtained after collagenase treatment of
adipose tissue [2]. SVF contains MSCs called adipose
tissue-derived stem cells (ASCs), which are able to diﬀerenti-
ate in bone, cartilage, and adipose tissue [7, 8] and have been
successfully used in human patients without the need of a
surgical procedure [9]. In the last decade, many clinical trials
tested infusion of ASCs or SVF alone or in combination
with platelet-rich plasma (PRP): they not only showed
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encouraging results in regenerating cartilage in patients
with large cartilage lesions or with osteoarthritis (OA)
but also report improvement in orthopaedic scores for
pain, function, range of motion, and MRI evidence of
cartilage regeneration [9–11]. Often in OA, there is a con-
comitant subchondral bone damage; thus, a role of SVF in
regeneration of bone is envisioned. Moreover, other path-
ological conditions (e.g., osteonecrosis of femoral head,
bone fracture, and nonunion fractures) could beneﬁt from
the SVF ability to regenerate bone.
In order to improve bone regeneration, diﬀerent scaﬀolds
have been generated, using diﬀerent biomaterials, and recent
trends point towards a composite approach for best mimick-
ing the human bone structure [12]. In this framework,
SmartBone (SB), a xenohybrid bone graft [13], resulted to
be particularly eﬃcient: it is commercially available as a med-
ical device, and it was initially developed as a bone substitute
for reconstructive surgeries in the presence of bone losses,
giving excellent results [13, 14]. SB is constituted of a bovine
bone matrix reinforced by a micrometric thin poly(l-lactic-
co-ε-caprolactone) ﬁlm embedding RGD-containing colla-
gen fragments (extracted by puriﬁed bovine gelatin), which
overall results in increased mechanical properties, hydrophi-
licity, cell adhesion, and osteogenicity [14]. In order to deeply
investigate the basic biological mechanisms beneath the
recorded clinical performances of such a graft and to investi-
gate the bone-regenerative potential of ASCs and SVF, we
studied their ability to colonize SB and generate new tissue
when cultured on it [15].
2. Materials and Method
2.1. Isolation of SVF from Adipose Tissue. SVFs were isolated
from fresh adipose tissue derived from 7 patients, who pro-
vided written consent according to the approval of the Ethi-
cal Committee of our institution. Seven lipoaspirates were
processed according to a previously published procedure
[3]. Brieﬂy, after enzymatic digestion with Collagenase NB4
(SERVA Electrophoresis) and subsequent washes with saline
solution, the cell pellets were treated with a cell lysis solution
(Promega) to discard blood cells, then cells were collected
and counted. The phenotype of ASCs contained in the SVF
was evaluated by ﬂow cytometry, soon after SVF isolation.
2.2. Flow Cytometry Analysis. Mesenchymal cell surface
markers were analysed by ﬂow cytometry on fresh SVF and
on cultured ASCs. A standard labelling protocol was
performed with the following antibody ﬂuorochrome-
conjugated and isotypic controls: human CD105 PE (Invitro-
gen), CD73 FITC (kindly provided by Prof. Malavasi,
University of Turin), CD44 FITC, CD45 PerCP, CD271
APC, IgG1 PE, IgG1 APC and IgG2a PerCP (Miltenyi
Biotec), and IgG1 FITC conjugate (IMMUNOSTEP). About
105 events/sample were used for capture with CellQuest
software. All data were analysed with Flowlogic software
(Miltenyi Biotec).
2.3. Scaﬀold Preparation. The xenohybrid bone scaﬀold,
SB, was produced according to a previously published
method [14]. SB discs (7× 3mm—made to ﬁt into
multiwells) were washed twice with saline buﬀer solution
then kept in α-MEM to improve hydrophilicity and the
subsequent cell seeding.
2.4. Cell Cultures. To obtain a population of ASCs, the
SVF cells were seeded in T25 ﬂasks and cultured in
DMEM with 10% FBS, 2mM glutamine, and 1% antibiotics
(Gibco, Life Technologies), and the medium was replaced
to eliminate nonadherent cells after 24 h. Cell cultures were
maintained, and ASCs at the 2nd passage were utilized for
all experimental settings.
SVF and ASCs were cultured on tissue culture plastic
and on SB discs at a concentration of 1× 106 SVF cells
and 1× 105 ASCs for 60 days, in α-MEM with 10% FBS,
2mM glutamine, and 1% antibiotics (Gibco, Life technolo-
gies) or in osteogenic medium (OM) containing α-MEM
supplemented with 10% FBS, 50μg/ml ascorbic acid,
10−8M dexamethasone, and 10mM beta-glycerophosphate
(Sigma-Aldrich). The medium was replaced twice a week.
At 15, 30, and 60 days, cells cultured on tissue culture
plastic were stained for alkaline phosphatase (ALP) accord-
ing to the kit produced by Sigma-Aldrich to monitor the
osteoblast (OB) diﬀerentiation. The mineralization activity
of OBs was evaluated through the detection of mineralized
nodules by von Kossa staining.
2.5. Real-Time qRT-PCR. After 15, 30, and 60 days, we
isolated cells from SB by treating them with collagenase I
(SERVA) for 30 minutes, then cells were washed and
dissolved in TRIzol reagent for RNA extraction by the Ribo-
Pure kit procedure (Ambion). One microgram of RNA
was converted up to single-stranded cDNA by the High-
Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems). Quantitative real-time PCR was performed by
the CFX96 system (Bio-Rad). The mRNA expression of
the following genes was tested: osteocalcin (OCN,
NM_199173.5), alkaline phosphatase (ALP, NM_000478.5),
RUNX2 (NM_001024630.3), and collagen 1 (COLL-1,
NM_000088.3); the primer sequences of the ﬁrst 3 genes were
previously published [16], whereas we designed and tested
COLL-1 FW primer CTGTTCTGTTCCTTGTGTAAC and
COLL-1 REV primer GCCCCGGTGACACATCAA. RT-
PCR was performed with SensiFAST™ SYBR Hi-ROX
kit (Bioline). The ampliﬁcation protocol foresees 40
cycles with a Tm of 58°C. The expression of β-actin
was chosen to normalize gene expression data and the
2−ΔΔCt method for the quantitative analysis with CFX
Manager software (Bio-Rad).
2.6. Micro-CT. SB was analysed by high-resolution X-ray
microtomography (SkyScan 1172, Bruker) to study the struc-
ture and to compare the volumes of SB before and after SVF
and ASC colonization. Acquisitions were performed at 80 kV
using a 0.5mm Al ﬁlter at a resolution of 6μm, 0.4° of rota-
tion step, 360° scan, and 4x frame averaging. Datasets were
reconstructed with NRecon software (Bruker), and quantiﬁ-
cation was performed by two expert operators on axial slices,
measuring the mineralized tissue length by using DataViewer
2 Stem Cells International
software (Bruker). A color contrast mask was used to allow a
clear identiﬁcation of newly formed mineralized tissue.
2.7. Scanning Electron Microscopy (SEM) Analysis. As previ-
ously shown [14], visual assessment of cell layering on SB
was performed via environmental SEM, both on unseeded
and seeded samples at 10 kV with EVO 50 EP Instrumenta-
tion (Zeiss, Jena, Germany). At the end of the cell culture
studies, scaﬀolds were ﬁxed with 2.5% (v/v) glutaraldehyde
solution in 0.1M sodium cacodylate buﬀer for 1 h at 4°C,
washed with sodium cacodylate buﬀer, and then dehydrated
at room temperature in a gradient ethanol series up to 100%.
At 15, 30, and 60 days, each sample was analysed on the side
external surfaces and then halved with a sharp scalpel and the
two inner exposed surfaces were internally analysed.
2.8. Histochemical Analyses. SB discs were ﬁxed in a neutral
buﬀer containing 4% formaldehyde, washed, and decalciﬁed
with MicroDec EDTA-based from Diapath. Specimens were
then dehydrated and paraﬃn-embedded through EZ Prep
Concentrate solution (Ventana Medical Systems Inc.). Sec-
tions were stained for H&E for morphological analyses.
Immunohistochemical analysis (IHC) was performed by
the automated instrument BenchMark ULTRA (Ventana).
Tissue sections were incubated with the following primary
mouse monoclonal antibodies (MoAb) from Abcam:
COLL-1 (ab34710, at 1 : 400 dilution), OCN (ab93876, at
dilution 1 : 250), and TGFβ (ab92486, at dilution 1 : 150).
They were titrated to yield maximal speciﬁc staining and
minimal nonspeciﬁc or background staining. The endoge-
nous peroxidase activity was inhibited by the addition of
ultraView Universal DAB Detection Kit (Ventana). All sam-
ples were counter-stained with Mayer’s hematoxylin solution
(Roche) and mounted with Kaiser’s glycerol gelatin. Slides
were examined double blind, and microphotographs were
taken using an Olympus BX51 microscope equipped with a
digital camera (Nikon DCS E995).
2.9. ELISA. The expression levels of vascular endothelial
growth factor (VEGF) and endothelin-1 (ET-1) in cell cul-
ture supernatants were determined by a commercially avail-
able Quantikine ELISA kit according to the manufacturer’s
instructions (R&D Systems). Supernatant samples were col-
lected at days 4, 15, 30, and 60 of culture. Day 4 is the starting
point of the analysis and is therefore referred to as day 0 in
the graphs: indeed, the cells need to grow for a few days (from
day 0 to day 4) and are used for analysis. Samples were
assayed in duplicate, and data were expressed as mean values.
2.10. Statistical Analysis. All statistical analysis was carried
out using GraphPad Prism 4. Data were presented as mean
with standard error. Data were analysed by one-way
ANOVA with Bonferroni’s multiple comparison test. To
evaluate signiﬁcant diﬀerences in the means of newly miner-
alized tissue length, at least 150 bone-like segments for each
conditions were measured. Results were considered signiﬁ-
cant with p < 0 05.
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Figure 1: Flow cytometry analysis of mesenchymal cells in freshly isolated and cultured SVF. Dot plots show the morphology of SVF (a) and
ASCs (e). SVF is a heterogeneous cell population, containing CD105-, CD44-, CD73-, and CD271-positive mesenchymal cells (b, c) and a
small fraction of CD45-positive cells (d), due to the normal presence of leukocytes in SVF. After 15 days of culture, a large and enriched
population of ASCs highly expresses mesenchymal markers (f, g), whereas it is completely negative for CD45.
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3. Results
3.1. Phenotypical Analysis of SVF and ASCs. Amean of 7% of
ASCs coexpressed CD105, CD44, CD73, and CD271 and
were CD45-negative, with a large range of variability
(1.6–13.6%) due to human diﬀerences. Cells expressing
mesenchymal markers were present in freshly isolated
SVF (Figures 1(a)–1(d)) and resulted to be highly enriched
in ASCs derived from SVF in vitro culture for 15 days
(Figures 1(e)–1(h)). As expected, the leukocyte population
was present in SVF (Figure 1(d), CD45+ cells in the lower
right side of the dot plot), but it was completely absent in
the ASC culture after 15 days.
3.2. ASCs and SVF Diﬀerentiate into Osteoblasts In Vitro.
Both ASCs and SVF were cultured with or without OM
for 60 days and showed diﬀerentiating ability towards
osteoblasts (OBs) expressing ALP. Precisely, in the
absence of osteogenic factors (control conditions), ASCs
were ALP-negative (Figure 2(a)). On the contrary, ALP-
positive cells were detected in SVF cultures, suggesting the
presence of committed ASCs in SVF (Figure 2(b)). Both
ASCs and SVF cultures with OM were ALP-positive
(Figures 2(c)–2(d)). Next, we looked at the mineralization
ability of both ASCs and SVF by von Kossa staining, as a
readout of their activity. We observed that both types of
cells did not mineralize in the absence of OM
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Figure 2: In vitro osteoblastic diﬀerentiation of ASCs and SVF. ASCs and SVF were cultured in the absence (ctrl) or in the presence of
osteogenic medium (OM), for 60 days. In ctrl cultures, ALP expression is negative in ASCs (a), whereas it is positive in SVF (b). In the
presence of OM, both ASCs and SVF show ALP-positive cells (c, d). For both ASCs and SVF, von Kossa staining is negative in the
ctrl (e, f) and show mineral nodules with OM (g, h). Magniﬁcation 5x.
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(Figures 2(e)–2(e)), whereas they did it in the presence of
osteogenic factors (Figures 2(g)–2(h)).
3.3. ASCs and SVF Colonize SB. H&E staining performed on
SB cultured with ASCs and SVF showed the typical features
of bone tissue, with trabeculae and empty lacunae, due to
the complete decellularization of this biomaterial, particu-
larly of its bovine-derived matrix, as described by the manu-
facturer [13]. Both ASCs and SVF colonized SB and formed
new tissue on this biomaterial, starting from the periphery
of the SB and ﬁlling bone lacunae, as described also in clinical
studies [15]. We monitored the tissue growth at 15, 30, and
60 days, in both ASCs and SVF showing increasing areas of
new tissue during the time, with and without OM, suggesting
that SB is osteoinductive by itself (Figure 3).
To monitor and quantify the growth of ASCs and SVF on
SB, we assessed the presence of new tissue by micro-CT at
diﬀerent timepoints, showing a progressive increase inminer-
alized tissueappositionduring time, from15 to60days, both in
the absence and in the presence of osteogenic factors. The
newly formedbone-like segments present at 60days are shown
in Figure 4(a). The quantiﬁcation analysis of the newly formed
mineralized tissue demonstrated that SVFs were signiﬁcantly
more eﬃcient than ASCs in inducing bone formation when
cultured on SB with OM (Figure 4(a)). In the absence of
osteogenic factors, SVF showed an osteogenic capacity signif-
icantly lower than ASCs cultured under both conditions. No
signiﬁcant diﬀerences could be detected between ASCs
cultured on SB with or without OM (Figure 4(b)).
SEM analyses also corroborated these data; indeed, we
detected a marked new tissue formation on SB cultured with
SVF (Figures 5(a) and 5(c)) compared to ASCs (Figures 5(b)
and 5(d)) at 30 days and demonstrated a trend later detect-
able and quantiﬁed by micro-CT.
3.4. Expression of Osteoblast Markers by ASCs and SVF
Cultured on SB. To better characterise molecularly the cell
growth on SB both in the absence (ctrl) and in the presence
of OM, we evaluated the expression of an early osteogenic
marker (Runx2) and of mature osteoblast markers (ALP,
OCN, and COLL-1). We observed a modulation of the
expression of all genes in ASCs and SVF cultures on SB at
30 and 60 days compared to our starting point (15 days).
The highest increase in mRNA expression for all genes was
observed at 60 days (Figure 6), even though no statistically
signiﬁcant diﬀerences were reported.
To further conﬁrm this result, we performed ALP, OCN,
and TGFβ staining on SB, which is negative for their expres-
sion by itself (Figure S1). We checked the expression of these
proteins by cell growth on SB at 15 to 30 days of culture,
observing a progressive increase in protein staining with the
maximum expression at 60 days (Figure 7). Indeed, at 60
days, in control conditions, SB cultured with ASCs resulted
to be weakly positive for COLL-1 ﬁbers (Figures 7(a)),
whereas in culture with SVF, COLL-1 was highly expressed
(Figure 7(c)). In the presence of OM, both in cultures with
ASCs and SVF, COLL-1 markedly stained the new tissue on
SB (Figures 7(b) and 7(d)). OCN resulted to be weakly
positive in controls (Figures 7(e) and 7(g)), whereas it was
highly expressed with OM, mainly on the periphery of
the newly formed tissue (Figures 7(f) and 7(h)). TGFβ
highlighted OBs at the boundaries of the newly formed
tissue both with and without OM, with ASCs and SVF
(Figures 7(i)–7(l)). These data conﬁrm the potential of ASCs
and SVF to diﬀerentiate into OBs, when cultured on SB.
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Figure 3: H&E staining to monitor SB colonization by ASCs and SVF. Both ASCs (left panels) and SVF (right panels) grow on SB in the
absence of α-MEM or in osteogenic medium (OM). The presence of new tissue formation is evident since 15 days of culture, and it
increases over time. Images of H&E staining are reported for each time point (15, 30, and 60 days). Magniﬁcation 20x.
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Figure 4: Analysis of new bone formation by micro-CT. (a) Representative images of X-ray tomography of SB with and without osteogenic
medium (OM), after 60 days of culture with ASCs or SVF. The SB is shown in blue, whereas the newly formed mineralized tissue is in red (as
indicated by the arrows). (b) Quantiﬁcation of the newly formed mineralized tissue measured on SB cultured with ASCs or SVF, with or
without OM. ∗p < 0 05.
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Figure 5: Analysis of new bone formation by SEM. Representative SEM images depicting SB after 30 days of culture with ASCs (a, c) and
SVFs (b, d), respectively, at low (a, b) and high (c, d) magniﬁcations.
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Figure 6: mRNA expression of osteogenic markers in ASCs and SVF plated on SB. The expression of RUNX2 (a), ALP (b), OCN (c), and
COLL-1 (d) was analysed on ASCs and SVF plated on SB at 15, 30, and 60 days. A nonstatistically signiﬁcant modulation of the
expression of these genes was detected both without osteogenic factors (CTRL) and with OM.
ASC 훼-MEM SVF 훼-MEM SVF OMASC OM
Magnification 20x
Co
ll-
1
O
CN
TG
F훽
(a) (b) (c) (d)
(e) (f) (g) (h)
(i) (j) (k) (l)
Figure 7: Osteoblast diﬀerentiation of ASCs and SVF on SmartBone. At 60 days, in ctrl condition, collagen I (COLL I) was weakly positive on
SmartBone cultured with ASCs (a), whereas in culture with SVF, COLL I was expressed (c). Both in cultures with ASCs and SVF with
osteogenic medium (OM), COLL I markedly stained the new tissue on SmartBone (b, d). Osteocalcin (OCN) was weakly positive in ctrl
(e, g), and it was highly expressed with OM, mainly on the periphery of the newly formed tissue (f, h). TGFb stained osteoblasts at the
margin of the newly formed tissue both with and without OM, with ASCs and SVF (i–l). Magniﬁcation: 20x.
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3.5. Endothelin-1 and VEGF Are Produced by ASCs and SVF
Plated on SB. The levels of ET-1 and VEGF were dosed in SB
cell culture supernatants at the beginning and over the cul-
ture. In ASC cultures, both ET-1 and VEGF were produced
with and without osteogenic factors. ET-1 levels tend to
decrease at 60 days (Figure 8(a)), whereas high VEGF levels
were constantly released over time (Figure 8(b)). In SVF
cultures, the ET-1 level increased with osteogenic factors,
whereas its production was variable with regular medium
(Figure 8(c)). VEGF levels were increased until 30 days of
culture, then they decreased both with and without osteo-
genic factors (Figure 8(d)). In both ASC and SVF cultures,
with or without osteogenic factors, the levels of VEGF and
ET-1 were not signiﬁcantly diﬀerent by statistical analysis.
4. Discussion
Human ASCs hold great potential for regenerative medicine
applications. In this study, we demonstrated the eﬃcacy of
ASC-driven reconstruction of bone using SB, a xenohybrid
bone graft scaﬀold. Importantly for clinical implications, we
showed that SVF (the noncultured fraction of ASCs) has an
osteoinductive ability on SB better than ASCs in the presence
of osteogenic factors.
The regenerative ability of SVF derived from adipose tis-
sue depends on soluble factors released and also on the pres-
ence in SVF of ASCs, which have multipotent diﬀerentiating
capabilities. Indeed, SVF is a heterogeneous cell population
containing endothelial cells, pericytes, leukocytes, red blood
cells, and mesenchymal stem cells. ASCs can be derived from
an in vitro cell culture of SVF. According to literature data,
the ASC percentage in SVF is extremely diﬀerent among
patients, due to the human variability [17]. After 15 days of
culture, we obtained an enrichment of the mesenchymal
population initially present in SVF. ASCs expressed the typ-
ical mesenchymal markers CD105, CD73, CD44, and CD271
and were CD45-negative, as previously reported by literature
data [3, 18–20]. Speciﬁcally, in our patients, the mean per-
centage of mesenchymal stem cells in freshly isolated SVF
was 7%. The ability of ASCs to diﬀerentiate into OBs, chon-
drocytes, and adipocytes according to the diﬀerent stimuli
received has been deeply investigated by us and other groups
[3, 5]. Here, we studied the osteogenic diﬀerentiating ability
of ASCs and SVF, by comparing the ability to grow both in
plastic and on SB, in regular and osteogenic media. Both
ASCs and SVF diﬀerentiated into OBs expressing ALP and
were able to mineralize when cultured in OM. ASCs were
ALP-negative in the absence of osteogenic factors, whereas
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Figure 8: Secretion of ET1 and VEGF by ASCs and SVF plated on SB by ELISA assay. The levels of ET-1 and VEGF were dosed in cell culture
supernatants at the beginning and during the culture. In ASC cultures, both ET-1 and VEGF were produced with and without osteogenic
factors. ET-1 levels decreased, whereas high VEGF levels were constantly released over time (a, b). In SVF cultures, ET-1 showed an
increasing trend of secretion with osteogenic factors, compared to a variable production in regular medium (c). VEGF levels increased
until 30 days of culture, then they decreased with and without osteogenic factors (d).
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in SVF cultures we detected ALP-positive cells, suggesting
the presence of committed ASCs in SVF. Even though
osteogenic ALP-positive OBs were present in SVF, they
did not mineralize, suggesting that microenvironmental
factors play a key role in promoting the complete activation
of these cells.
In order to improve bone regeneration, diﬀerent bioma-
terials and scaﬀolds have been generated and tested: recent
trends point towards a composite approach for best mimick-
ing the human bone structure [12]. In this framework, we
tested SB to study its supporting properties on mesenchymal
cells and to evaluate the capabilities of ASCs and SVF to
colonize and generate new tissue on it. After plating ASCs
and SVF on SB, we monitored the tissue growth at 15, 30,
and 60 days, showing increasing areas of new tissue over time
with and without OM, suggesting that SB is osteoinductive by
itself. By H&E staining, we showed that cells spread inside the
SB scaﬀold, with a massive cell proliferation. The growth of
ASCs and SVF on SB starts from the periphery of the SB,
and then cells ﬁll bone lacunas. The ability of mesenchymal
cells to colonize and grow on SB, creating new tissue, explains
and conﬁrms the previously described osteointegrative
capability of SB [15]. New bone formation within the bone
substitute specimens was analysed recurring to micro-CT
and SEM analyses. Interestingly, SVF cultured on SB
resulted to be more eﬀective than puriﬁed ASCs in promot-
ing mineralized tissue apposition in vitro, based on the
bone-like segment quantiﬁcation of the scaﬀolds. Although
the experimental setup is diﬀerent and thus not entirely
comparable, these ﬁndings are not completely in accordance
with the in vivo study by Cheung et al. [21] who reported a
similar mineral density for ASCs and SVFs. It should be
underscored, however, that the data here presented may
at least support the use of SVF to enhance inorganic bone
substitutes, as recently proposed by Prins et al. [22],
where SVF supplementation on either β-tricalcium phos-
phate or biphasic calcium phosphate carriers proved to
be clinically useful.
To characterise molecularly the cells grown on SB in both
regular and osteogenic media, we detected the expression of
early markers of osteogenic diﬀerentiation of Runx2 and
ALP and of mature osteoblast markers OCN and COLL-1
[23]. As expected, osteogenic medium increased the expres-
sion of all genes over time in our patients compared to
medium without osteogenic factors, although this increase
was not statistically signiﬁcant between the two conditions.
An enlarged panel of patients is needed to overcome the
limitations of human variability and to give a statistical
power to the analysis.
When we looked at the protein expression, we observed
by IHC that in SVF culture, new tissue was markedly stained
for COLL-1, OCN, and TGFβ even in the absence of osteo-
genic factor stimulation, whereas in ASC culture the staining
was detectable only with osteogenic medium. This result
further conﬁrms the micro-CT data on the high ability of
SVF to colonize and generate new tissue on SB.
All those data open the debate on how it is possible that a
smaller number of ASCs, present in freshly isolated SVF,
compared to the expanded ASCs, could generate more tissue.
We believe that all the diﬀerent cell populations present in
SVF likely cooperate and stimulate mesenchymal cell activity
better than the ASCs alone, conﬁrming the fundamental
interplay between stem cells and the microenvironment.
Indeed, previous studies had shown that human ASCs closely
interact with vascular endothelial cells and secrete cytokines
and growth factors (ASCs’ secretome) into the extracellular
milieu, with eﬀects on diﬀerent organs/systems within the
human body [24, 25]. Among them, VEGF [26] and ET-1
[27] are paracrine factors secreted by ASCs that could pro-
mote OB diﬀerentiation. VEGF is not only a critical mediator
in physiological angiogenesis but also a vital factor in skeletal
growth. VEGF plays a positive role in the regulation of oste-
oblasts [28]: it has been reported that VEGF is expressed in
osteoblast-like cells in a diﬀerentiation-dependent manner
[29]. Studies on animal models showed how a combination
of VEGF released from scaﬀolds previously seeded with bone
marrow-derived MSCs (BM-MSCs) to the sites of bone dam-
age resulted in increased regeneration of the bone defects
[30]. Similarly, ET1 is involved in the regulation of osteo-
genic diﬀerentiation [31, 32], and it has been shown to be
an important upregulator of MSC osteogenic and chondro-
genic capacities [33, 34].
In order to better investigate the molecular signals
responsible for successful bone regeneration in our model,
we dosed VEGF and ET-1 secreted in cell culture superna-
tants over time, in the absence or presence of osteogenic fac-
tors. According to literature data, we observed a secretion of
both VEGF and ET1 in MSCs after osteogenic diﬀerentiation
in vitro. In particular, VEGF showed a more solid trend of
increased secretion, while ET1 was more ﬂuctuating among
patients, likely due to human variability. These results con-
ﬁrm the importance of the adipose tissue-derived stem cell
secretome in osteogenesis.
In conclusion, our data demonstrate for the ﬁrst time
that SVF has better osteoinductive capabilities than ASCs
when plated on SB in osteogenic medium. Indeed, one of
the major limitations of therapy with ASCs derives from
the necessity to expand them in an in vitro culture, with the
consequent necessity to comply with the restrictive regula-
tory clearance of cell therapy protocols (Good Manufactur-
ing Practice). The absence of manipulation of SVF in an
in vitro culture could deﬁnitively represent a beneﬁt for a
larger use.
SVF could be particularly useful in diﬀerent clinical con-
ditions, characterised by loss of bone and cartilage. The most
common scenario is a localised osteocondral lesion of a large
weight-bearing joint in patients who suﬀered trauma, osteo-
condritis of the growing joint, osteonecrosis, or oncologic
resections. Defects of bone alone are also present in bone
tumor procedures as curettage of common benign lesions
such as ﬁbrous dysplasia, giant cell tumor of bone, aneurys-
mal bone cysts, or unicameral bone cysts, whose defect after
surgical procedure must be ﬁlled. Large bone defects or
nonunion fractures in long bone are often treated locally,
by injecting bone marrow-derived MSCs or ASCs in the
fracture site with good clinical outcomes. The detractors of
this technique criticise the diﬃculty in localising the stem
cells in the selected site. Therefore, regenerative medicine
9Stem Cells International
based on a solid scaﬀold such as the SB, already available as a
certiﬁed medical device, functionalised with SVF, could
improve the precision of stem cell implants and the quality
of new bone formation.
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